{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-011256","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.716172+00:00","generated_at":"2026-06-20T00:04:35.921758+00:00","sec_items":["1.01","1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jaguar Health and SynWorld Mutually Terminate License Agreement for Canalevia in Dogs in China","bullets":["Jaguar Health (NASDAQ:JAGX) and SynWorld Technologies terminated the exclusive license agreement for Canalevia (crofelemer) to treat diarrhea in dogs in China, effective January 31, 2023.","Termination is driven by Jaguar's 2023 strategic focus on human drug development, including Phase 3 OnTarget trial for cancer therapy-related diarrhea.","SynWorld's General Manager Tao Wang, a long-term shareholder of restricted Jaguar stock, fully supports the mutual termination decision.","All licenses granted to SynWorld under the agreement were revoked, and rights reverted back to Jaguar.","Jaguar expects enrollment in the OnTarget trial to complete in Q2 2023; also prioritizing proof-of-concept trial for short bowel syndrome and congenital diarrheal disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-011256","json":"https://secwatch.observer/filing/0001104659-23-011256.json","markdown":"https://secwatch.observer/filing/0001104659-23-011256.md","text":"https://secwatch.observer/filing/0001104659-23-011256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/0001104659-23-011256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/tm235360d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:04:35.921758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db4f0161b9ea871140a4be6664e94be89aaa1f6c","claim":"Jaguar Health, Inc. terminated License Agreement with SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang (effective 2023-01-31).","evidence_excerpt":"On January 31, 2023, the Company, Licensee, C&E Telecom and Wang entered into a Mutual Termination of License Agreement (the “Termination Agreement”), pursuant to which the parties agreed to mutually terminate the License Agreement, effective as of January 31, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/0001104659-23-011256-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang"},{"label":"Effective","value":"2023-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}